BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Strategic Appointment of World-Renowned Immunologist and Cytokine Expert

Company: FSD Pharma Inc. (HUGE)
Category: News

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the appointment of Eleanor N. Fish, Ph.D., to its research and clinical advisory board. Dr. Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the government of Canada’s expert scientific panel to the chief scientific advisor. She brings key expertise to FSD Pharma that will support the continued development of FSD-PEA, the company’s proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis. “I am delighted to welcome Dr. Eleanor Fish to our team,” said Dr. Lakshmi P. Kotra, B.Pharm (Hons), Ph.D., CEO of Lucid Psycheceuticals Inc., FSD Pharma’s wholly owned subsidiary. “A key aspect of Eleanor’s research is to better understand the onset and treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Her expertise and insights will be extremely valuable as we continue to advance our FSD-PEA and Lucid-MS programs, and her decades of experience in translational research will greatly benefit FSD’s current and future pipelines.”

To view the full press release, visit https://ibn.fm/q2fLJ

About FSD Pharma Inc.

FSD Pharma is a life sciences holding company with two wholly owned subsidiaries dedicated to building a portfolio of diversified therapeutic assets and innovative health care and biotech services. FSD BioSciences Inc., a wholly owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing applications of its lead compound, ultramicronized PEA, by down-regulating the cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a wholly-owned subsidiary, has exclusive worldwide rights to novel compounds shown to prevent and potentially reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, FSD is seeking to develop a unique psychoactive (psychedelic-based) therapeutic aimed at addressing neurodegenerative disorders, a multibillion-dollar mental health market. The company hopes to quickly advance its lead drug candidates through clinical trials. For more information, visit the company’s website at www.FSDPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050